IGF-I and Bone Loss in Women with Anorexia Nervosa
$629,351R01FY2013DKNIH
Massachusetts General Hospital, Boston MA
Investigators
Linked publications, trials & patents
Paper 37322610Paper 34355814Paper 31803857Paper 31219580Paper 30165608Paper 29659886Paper 29090684Paper 28152193Paper 27811940Paper 27797678Paper 27732336Paper 27527115Paper 26509295Paper 26332401Paper 26171799Paper 25062461Paper 24953711Paper 24898127Paper 24430890Paper 24363451Paper 24011884Paper 23640801Paper 23512706Paper 23218167Paper 22733643Paper 22644889Paper 21976742Paper 21903023Paper 21525157Paper 20713613Paper 19931436Paper 19850693Paper 19747572Paper 19318450Paper 19158192Paper 18486583Paper 17592924Paper 17519306Paper 17284620Paper 16972186Paper 16735492Paper 15767533Paper 15664791Paper 15613421Paper 15356043Paper 15292338Paper 15292325Paper 15240636Paper 12915674Paper 12737712Paper 12629097Paper 12050268Paper 11333838Paper 11095413Paper 11085841Paper 10971454Paper 10942914Trial NCT01406444Trial NCT00089843
Abstract
DESCRIPTION (provided by applicant): Bone loss is a major, frequent and often permanent comorbid medical complication of anorexia nervosa (AN) affecting over half of all women with this disease and resulting in debilitating fractures, yet there are few effective therapies. In this proposal, we will test the effectiveness of a sequential therapeutic regimen designed to specifically: 1) reverse insulin-like growth factor 1 deficiency, thereby stimulating bone formation, and 2) reduce bone breakdown, using a bisphosphonate, a medication that is effective at reversing bone loss.
View original record on NIH RePORTER →